


### "Strategic Advice in an Era of Unprecedented Change"









Covid-19 "Vital Signs"

Issue # 282 February 10, 2021

# Covid-19 "Vital Signs"

# Highlights

- Projected Immunity:
  - Our Current Projection scenario hints that we could achieve 70% immunity by July 1 (60% by May 30; 80% by August 2);
  - Our Bad Variant scenario delays 70% immunity by eight weeks, until August 27 (60% by July 18; 80% by October 23);
  - Our New Vaccines scenario accelerates 70% immunity by nearly four weeks, to June 6 (60% by May 9; 80% by July 1;
  - Combining the New Vaccines and Bad Variants into a single scenario serves to offset the adverse effects of the variants with the gains from more vaccinations;
  - Natural immunity serves an important role in achieving herd immunity, yet the media and public officials remain silent on its impact; we constructed a scenario that ignores natural immunity, relying solely on vaccines. In the scenario, 70% immunity is delayed until August 8, more than a month later than our Current Projection; we reach 60% on July 23 (nearly eleven weeks later than with our Current Projection); 80% on September 5, nine weeks later than our Current Projection).
- Protected cases, Covid-19 patient days, and deaths with Covid-19:
  - Projected Covid-19 cases fall each of the next four weeks, according to the ensemble forecast published yesterday by the Covid-19 Forcast Hub;
  - Projected deaths with Covid-19 drop each of the next four weeks, based on this same ensemble forecast;
  - Estimated infections rise, starting next week until late March, then
    plummet through the end of May, according to <u>projections published</u>
    by the Institute for Health Metrics and Evaluation (IHME) last
    Thursday; infections at the upcoming apex, however, fall short of
    matching levels experienced in late December;

- Estimated Covid-19 patient days free-fall through the end of May, according to IHME; Of note, IHME's projected February 9 census overestimated actual days by 15%;
- Estimated daily deaths with Covid-19 free-fall through the end of May, too, according to IHME's model. IHME's 5-day-old projection overestimated the most recent death rate by 5%.
- Vaccination Progress:
  - The US vaccinated an average of 1.5 million people each day over the last week. Our Current Projection model calls for 1.2 million per day, until March 1, when the JNJ vaccine boosts this to 1.8 million daily; Vaccinations outpaced this target eleven times in the past two weeks;
  - Vaccines are being administered as soon as available far better than earlier in the process. As of yesterday, we have injected 71% of distributed doses, compared to 35% in early-January. The number of unused doses has hovered consistently at about 18 million.
- Tests, cases, infections, hospitalization, and death rates:
  - The Reproduction Rate (Rt) is falling, despite concerns about new variants, according to <u>Gu's projection model</u>; this rate declined seven consecutive days and has been below 1.0 (signaling decreasing infections) for thirty straight days;
  - Estimated new infections (Yale/Harvard and Gu models), as well as the 7-day new case rate in the US continue to fall from early-January peaks;
  - Covid-19 patient days plunged 40% over the past four weeks;
  - Test-positivity fell each of the past three weeks; the current rate hovers just above the lowest level achieved during the pandemic.



# **Immunity Projection Model**

- HIA crafted this Immunity projection model to illustrate when the US could reach <u>herd</u> <u>immunity</u>, based on certain assumptions about:
  - Approved vaccines and dates of availability
  - Vaccine efficacy
  - Natural (infection) immunity
  - Immunity required for herd immunity
  - Time lag from infection or vaccination to immunity
- The model is for illustration purposes and cannot predict when herd immunity will occur; Instead, we strive to be *directionally correct* and to assess the impact of certain scenarios:
  - The level of immunity required for her immunity
  - Possible approval of additional vaccines
  - Impact of emerging variants on:
    - infections rates,
    - sustainability of immunity from infection and
    - vaccine efficacy

# **Immunity Projection Model - Scenarios**


- Our Current Projection model:
  - Reflects the current vaccination pace (we assume 1.2M doses per day; average has been 1.3M), increasing proportionally with each new vaccine approved
  - All <u>presumed</u> US contracts for approved (EUAs for Pfizer and Moderna) and soon-to-be-approved vaccines (JNJ, EUA anticipated in late-February)
  - Natural immunity based on Gu's mean estimated infections
  - Two-week lag from infection or vaccination to immunity; no degradation in immunity over time
- Our Worse Case (not necessarily Worst Case); aka "Bad Variants":
  - New variants (UK, South African, Brazilian or others
  - Variants drive:
    - 20% increase in daily infection rate
    - 20% reduction in vaccine efficacy
    - 20% degradation in natural immunity
- Our <u>Better Case</u> (not necessarily Best Case); aka "New Vaccines":
  - Vaccines from AstraZeneca and Novavax receive EUAs (April 1 and July, respectively)
  - Ignores impact of "Bad Variants"

Note: we also show a combination of the Bad Variants and New Vaccines




### **Immunity Projections**

Our Current Projection shows herd immunity reached between May 30 and August 2; with the Bad Variants, it is delayed until July 18 to October 23; with the New Vaccines, it is accelerated to May 9 to July 1. New Vaccines tend to blunt the impact of Bad Variants





# **Immunity Projections - Timeline**




For illustration purposes only. Timeline is highly-dependent on the underlying assumptions. Results will likely vary from these projections.



### Covid-19 Cases: Ensemble Forecast

Projected new cases drop each week during the four-week forecast period









# Death Projections – Ensemble Forecast

Projected daily deaths fall each week of the forecast period; Cumulative deaths with Covid-19 surpass 500k near the end of February






https://viz.covid19forecasthub.org



Covid-19 "Vital Signs"

# **Estimated Infections IHME Projection**


IHME projects estimated infections to rise beginning next week through the end of March - but, not to return to recent peak levels. Estimated infections drop throughout April and May



Covid-19 "Vital Signs"

# Covid-19 Inpatients – IHME Projections


IHME envisions Covid-19 inpatient days to continue falling. Of note, actual Covid-19 patient days fell further already than IHME projected just five days ago



Covid-19 "Vital Signs"

# Deaths With Covid-19: IHME Projection


IHME expects deaths with Covid-19 to continue falling through the end of May. Of note, deaths over the past seven days are already lower than IHME's projection made just five days ago



# Covid-19 "Vital Signs"

### Pace of Vaccinations


Vaccinations surpassed our Current Projection on eleven of the past fourteen days; Two of the three "misses" occurred during last week's widespread snowstorm.





# Vaccine Tracking

To date, the US has administered 44.4 million doses, with 10.2 million people receiving two pokes.




Vaccine data from: Centers for Disease Control and Prevention and Bloomberg Vaccine Tracker





### Vaccines Distributed v. Unused


The US is delivering more shots to arms lately, while the number of doses queued for use has steadied.



Covid-19 "Vital Signs"

### Vaccines Distributed v. Administered


The US administered seven-in-ten of all doses distributed. North Dakota and Utah perform best, administering nearly all available doses; Rhode Island and Alabama administered 60% of available doses.





# Reproduction Rate (R<sub>t</sub>) – Gu\* Model

Gu's estimate of  $R_t$  remained below 1.0 for the thirtieth straight day. This rate declined each of the most recent seven days reported.






Covid-19 "Vital Signs"

# Estimated Daily Infections & New Case Rates

Estimated new infections and reported cases are plunging in the US. Note that estimated actual infections were much higher in November and December than detected cases, reflecting the high test-positivity during that time. This implies that actual infections are dropping much faster than reported cases.

#### • Two models:

- Youyang Gu: <u>https://covid19-projections.com</u>
- Yale School of Public Health: <a href="https://covidestim.gorg">https://covidestim.gorg</a>
- Gu model lags by two weeks








### Week-Over-Week Changes in New Cases

On a week-over-week basis , US and worldwide new cases sank each of the past twenty-six days






Covid-19 "Vital Signs"

# Newly Detected Cases / Million

Many hard-hit countries welcomed declining case rates in the past several weeks. Israel's case rate moderated yet remains high. Countries tied to new variants boast either declining (South Africa, UK and US) or low rates (Brazil)








### Newly Detected Cases / Million - US

Newly detected cases (7-day average) in the US declined for the twenty-ninth straight day – plunging a remarkable 58% in that time. This rate lags those posted everyday since November 6.








# Newly Detected Cases Per Day

Worldwide and in the US, 7-day new case rates receded during each of the past three weeks








# Infection Prevalence By State

South Dakota outpaces every other state in estimated infection prevalence, followed by North Dakota, Mississippi, New Jersey, Tennessee, and New York. Maine, Vermont and Hawaii occupy the tail-end of this ranking.








### Estimated Immunity Levels By State

An estimated four-in-ten residents of North and South Dakota enjoy immunity from Covid-19; for the US, it is three-in-ten. In Hawaii and Vermont, nine-in-ten residents are not immune from infection.









### New Cases / Million

Much of the US rebounded from the high infection rates seen early in January. Parts of the country, however, still suffer from rates higher than seen in the Summer and Fall, 2020.

### January 12

### February 9







Note the change in scale from previous reports. This was done to better depict the changing case rates.




Covid-19 "Vital Signs"

**Covid-19 Hospitalizations** *Covid-19 hospitalizations plunged over the past month, with 53,000 fewer* patients yesterday than on January 6 (40%). Yesterday's Covid-19 census fell to its lowest point since November 17. ICU and ventilator days declined each of the past three weeks.













# Covid-19 Hospitalizations

Covid-19 hospital census plunged in the past four weeks. Covid-19 patients occupied 25% of US beds yesterday versus 42% four weeks ago.

### January 12

### February 9











# Testing (US)

Test volume for the past seven days dropped from each of the prior three weeks – are fewer people fearing a recent exposure? The test-positive rate improved over the three preceding weeks.










# **Deaths Reported With Coronavirus**

The 7-day average death rate crept lower than it has been for each of the prior three weeks.







### Sources

The following data sources are accessed on a daily or weekly basis

- The Atlantic's Covid Tracking Project: <a href="https://covidtracking.com">https://covidtracking.com</a>
- Worldometers.info: https://www.worldometers.info/coronavirus/
- Centers for Disease Control and Prevention, National, Regional, and State Level Outpatient Illness and Viral Surveillance <a href="https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html">https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html</a>
- Centers for Disease Control and Prevention, COVID-19 Laboratory-Confirmed Hospitalizations https://gis.cdc.gov/grasp/COVIDNet/COVID19 5.html
- Centers for Disease Control and Prevention, COVID Data Tracker <a href="https://www.cdc.gov/covid-data-tracker/index.html#mobility">https://www.cdc.gov/covid-data-tracker/index.html#mobility</a>
- Centers for Disease Control and Prevention, Vaccines, <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html</a>
- Institute for Health Metrics and Evaluation, COVID-19 estimate downloads <a href="http://www.healthdata.org/covid/data-downloads">http://www.healthdata.org/covid/data-downloads</a>
- New York Times, Covid-19 data <a href="https://github.com/nytimes/covid-19-data">https://github.com/nytimes/covid-19-data</a>
- COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University https://github.com/CSSEGISandData/COVID-19
- COVID-19 Projections Using Machine Learning, <a href="https://covid19-projections.com">https://covid19-projections.com</a>
- Covid-19 Forecast Hub, <a href="https://viz.covid19forecasthub.org">https://viz.covid19forecasthub.org</a>
- Oliver Wyman Pandemic Navigator, https://pandemicnavigator.oliverwyman.com/forecast?mode=country&region=United%20States&panel=mortality
- Rt.live
- Yale School of Public Health & Harvard TH Chan School of Public Health, <a href="https://covidestim.org">https://covidestim.org</a>
- Bloomberg Vaccine Trackers, <a href="https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/?sref=Z0b6TmHW">https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/?sref=Z0b6TmHW</a>

